EUVIMEDEUVIMED entdecken
Leserbrief

The Clinical Utility of MPO / PON1 and MPO / HDL ‐C Ratios in Cardiovascular Risk Assessment

Wei-Jia Meng, Sha-Sha Zhu iD

Therapeutic Apheresis and Dialysis · 2026-12 · 30 (6) · 971-972

DOI: 10.1002/1744-9987.70152 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Therapeutic Apheresis and Dialysis, online erschienen am 03.05.2026. Verfasst von Wei-Jia Meng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrated Chinese and Western Medicine, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, China. Die Arbeit nennt 4 Literaturangaben. Gefördert von: Zhejiang Provincial College Students' Science and Technology Innovation Program.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Integrated Chinese and Western Medicine, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, China.

ORCID-Profile: Sha-Sha Zhu

Förderung

  • Zhejiang Provincial College Students' Science and Technology Innovation Program

Zitieren

APA

Meng, W. J., & Zhu, S. S. (2026). The Clinical Utility of MPO / PON1 and MPO / HDL ‐C Ratios in Cardiovascular Risk Assessment. Therapeutic Apheresis and Dialysis, 30(6), 971-972. https://doi.org/10.1002/1744-9987.70152

Vancouver

Meng WJ, Zhu SS. The Clinical Utility of MPO / PON1 and MPO / HDL ‐C Ratios in Cardiovascular Risk Assessment. Therapeutic Apheresis and Dialysis. 2026;30(6):971-972. doi:10.1002/1744-9987.70152

BibTeX
@article{Meng2026,
  author = {Meng, Wei-Jia and Zhu, Sha-Sha},
  title = {The Clinical Utility of MPO / PON1 and MPO / HDL ‐C Ratios in Cardiovascular Risk Assessment},
  journal = {Therapeutic Apheresis and Dialysis},
  year = {2026},
  volume = {30},
  number = {6},
  pages = {971--972},
  doi = {10.1002/1744-9987.70152}
}
Kostenlos starten →